Literature DB >> 8695259

Mutant p53 protein as a predictor of survival in endometrial carcinoma.

P Strang1, B Nordstöm, S Nilsson, R Bergström, B Tribukait.   

Abstract

The expression of mutated p53 protein was studied in paraffin-embedded, formalin-fixed tumour specimens from 183 women with endometrial carcinoma. Fifty-five per cent of the specimens were negative, whereas the staining intensity was weak, moderate or strong in 15, 2 and 28% of cases, respectively. Strong p53 expression (> 75% of the cells stained) was more common in uterine papillary serous cancers and clear cell cancers than in other tumour subtypes (P < 0.001), as well as in poorly differentiated tumours (P < 0.01) and in tumours with nuclear grade 3 (P < 0.0001). Strong p53 expression was also more frequently found in aneuploid tumours (P < 0.0001) and in tumours with a high S-phase fraction (P < 0.001). Strong p53 expression was highly predictive of poor survival in the univariate analysis (P = 0.006) and in the Cox multivariate analysis which included age, stage and grade. However, it lost most of its impact when the strongly prognostic nuclear grade and ploidy were added to the multivariate models.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695259     DOI: 10.1016/0959-8049(95)00636-2

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  5 in total

1.  Detection of p53 in inflammatory tissue and lymphocytes using immunohistology and flow cytometry: a critical comment.

Authors:  A Nickels; H Selter; M Pfreundschuh; M Montenarh; B Koch
Journal:  J Clin Pathol       Date:  1997-08       Impact factor: 3.411

2.  Laminin-5 gamma2-chain expression and DNA ploidy as predictors of prognosis in endometrial carcinoma.

Authors:  C Lundgren; B Frankendal; C Silfverswärd; B Nilsson; K Tryggvason; G Auer; B Nordström
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

3.  Type I to type II ovarian carcinoma progression: mutant Trp53 or Pik3ca confers a more aggressive tumor phenotype in a mouse model of ovarian cancer.

Authors:  Rong Wu; Suzanne J Baker; Tom C Hu; Kyle M Norman; Eric R Fearon; Kathleen R Cho
Journal:  Am J Pathol       Date:  2013-04       Impact factor: 4.307

Review 4.  Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers.

Authors:  Z Ping Lin; Yong-Lian Zhu; Elena S Ratner
Journal:  Front Oncol       Date:  2018-08-08       Impact factor: 6.244

Review 5.  The Association and Significance of p53 in Gynecologic Cancers: The Potential of Targeted Therapy.

Authors:  Mitsuhiro Nakamura; Takeshi Obata; Takiko Daikoku; Hiroshi Fujiwara
Journal:  Int J Mol Sci       Date:  2019-11-04       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.